Loading clinical trials...
Loading clinical trials...
An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
Conditions
Interventions
SAGE-547
Locations
17
United States
Sage Investigational Site
Birmingham, Alabama, United States
Sage Investigational Site
Sarasota, Florida, United States
Sage Investigational Site
Chicago, Illinois, United States
Sage Investigational Site
Wichita, Kansas, United States
Sage Investigational Site
New Orleans, Louisiana, United States
Sage Investigational Site
Boston, Massachusetts, United States
Start Date
March 21, 2014
Primary Completion Date
May 3, 2015
Completion Date
May 3, 2015
Last Updated
September 15, 2025
Lead Sponsor
Supernus Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions